Malignant Pleural Effusion

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Candel Therapeutics
1 program
1
AdV-tk + valacyclovirPhase 1Small Molecule1 trial
Active Trials
NCT01997190CompletedEst. Feb 2018
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
Aspira CatheterN/A1 trial
Active Trials
NCT03414905CompletedEst. Feb 2024
Rocket Pharmaceuticals
1 program
Pleural proceduresN/A1 trial
Active Trials
NCT04793607Unknown50Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Candel TherapeuticsAdV-tk + valacyclovir
Rocket PharmaceuticalsPleural procedures
Merit MedicalAspira Catheter

Clinical Trials (3)

Total enrollment: 50 patients across 3 trials

NCT01997190Candel TherapeuticsAdV-tk + valacyclovir

Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion

Start: Oct 2013Est. completion: Feb 2018
Phase 1Completed

Interventions for Malignant Pleural Effusions Impact on Fatigue

Start: Sep 2020Est. completion: Oct 202150 patients
N/AUnknown

Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System

Start: Jul 2018Est. completion: Feb 2024
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space